Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
NCT04559425
Recruiting
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharma... Read More
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona +26 locations
Conditions: Heart Block Complete, Heart Block Second Degree
Register for Updates
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
NCT01919086
Completed
The purpose of this study is to see if researchers could get the same good results with less toxicity by using this new approach. We already know that the three drugs bortezomib, lenalidomide, and dexamethasone given together at the same time are effective. Most physicians therefore treat patients with multiple myeloma with the 3 drug combination. However, the researchers also know that the three drugs given together result in more side effects than when only 2 drugs (bortezomib and dexamethaso... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut +6 locations
Conditions: Multiple Myeloma (MM)
Register for Updates
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
NCT04474223
Recruiting
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Phoenix Children's Hospital/Dignity Health, Phoenix, Arizona +23 locations
Conditions: AVB - Atrioventricular Block, Fetal AVB
Register for Updates
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02101944
Completed
This phase I trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as dexamethasone and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A virus called w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia +2 locations
Conditions: Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.
NCT05721027
Recruiting
This will be a placebo controlled, randomized, double-blind, comparative effectiveness study, in which we patients are enrolled during an emergency department (ED) visit for acute radicular low back pain (LBP) and followed by telephone two and seven days later. Patients will be randomized to receive an oral dose of dexamethasone for 2 consecutive days or placebo during an ED visit for acute radicular LBP. Every patient will receive a 7 day supply of ibuprofen and a low back pain education sessio... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/14/2024
Locations: Albert Einstein College of Medicine/Montefiore Medical Center - Weiler ED, Bronx, New York +1 locations
Conditions: Radiculopathy, Lumbosacral Region, Back Pain With Radiation, Low Back Pain
Register for Updates
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
NCT02697383
Completed
The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +5 locations
Conditions: Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Register for Updates
Dexamethasone vs Ondansetron After Cesarean Delivery
NCT05692245
Completed
The goal of this clinical trial is to compare medications in women having a cesarean delivery. The main question it aims to answer are: • Which medication is better to use as a first-line prevention agent for nausea and vomiting Participants will rate their nausea, pain and other symptoms after surgery Researchers will compare two drugs, ondansetron and dexamethasone to see if the side effects of pain medications are improved after cesarean.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
05/06/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Nausea and Vomiting, Postoperative, Cesarean Section Complications
Register for Updates
Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures
NCT03898154
Recruiting
The purpose of this investigation is to compare functional outcome measures and range of motion for patients receiving glucocorticoid (GC) injections versus those not receiving GCs for the treatment of distal radius fractures. The investigators hypothesize that patients who receive GC will have improved ROM and functional outcome measures compared to patients who do not receive GC. In addition, this study aims to determine if there is a difference in rates of complications and postoperative pain... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Geisinger Woodbine, Danville, Pennsylvania
Conditions: Distal Radius Fracture
Register for Updates
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04045795
Completed
Primary Objectives: * To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) * To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device * To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: * To estimate absolute bioavailability of SC and IV isatuximab * To measure receptor occupancy (RO) after isatuximab SC v... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: ~Banner MD Anderson Cancer Center Site Number : 8400005, Gilbert, Arizona +13 locations
Conditions: Multiple Myeloma
Register for Updates
Hormonal Mechanisms of Sleep Restriction - Axis Study
NCT03142893
Active Not Recruiting
The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG axis) deactivation occurs with sleep restriction. The investigator will also examine the cognitive function associated with sleep restriction, including food intake and food cravings.
Gender:
MALE
Ages:
Between 22 years and 45 years
Trial Updated:
04/22/2024
Locations: Los Angeles Biomedical Research Institute, Torrance, California
Conditions: Sleep Restriction
Register for Updates
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT03860844
Terminated
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary Objectives: * Safety and tolerability assessments * Assessment of infusion reactions (IRs) * Pharmacokinetics (PK) of isatuximab * Minimal residual disease * Overall response rate * Overall survival * Event free surviv... Read More
Gender:
ALL
Ages:
Between 28 days and 17 years
Trial Updated:
04/22/2024
Locations: Sarah Cannon Research Institute-Site Number:8400001, Nashville, Tennessee +40 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Register for Updates
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
NCT01659658
Terminated
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic light chain (AL) amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +65 locations
Conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
Register for Updates